Macbecin

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: Macbecin
• 英文别名: (13,14,17-trimethoxy-4,8,10,12,16-pentamethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl) carbamate
• 化学式: C₃₀H₄₂N₂O₈
• 分子量: 558.7
• InChiKey: PLTGBUPHJAKFMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  40
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  143
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• METHODS AND COMPOSITIONS RELATING TO HEMATOLOGIC MALIGNANCIES
  申请人：Li Shaoguang

  公开号：US20120114605A1

  公开（公告）日：2012-05-10

  Methods of treating a subject having, or at risk of having, a myeloproliferative disorder are provided according to embodiments of the present invention which include administering a therapeutically effective amount of an arachidonate 5-lipoxygenase (5-LO) inhibitor to the subject. Combinations of therapeutic agents are administered according to embodiments of the present invention. In some embodiments, two or more 5-LO inhibitors are administered to a subject to treat a myeloproliferative disorder. In further embodiments, at least one 5-LO inhibitor and at least one additional therapeutic agent are administered to a subject to treat a myeloproliferative disorder. Methods of inhibiting leukemia stem cells are provided according to embodiments of the present invention which include contacting leukemia stem cells with an effective amount of an arachidonate 5-lipoxygenase inhibitor.
• US8669289B2
  申请人：——

  公开号：US8669289B2

  公开（公告）日：2014-03-11
• [EN] METHODS AND COMPOSITIONS RELATING TO HEMATOLOGIC MALIGNANCIES<br/>[FR] PROCÉDÉS ET COMPOSITIONS LIÉES À DES TUMEURS MALIGNES HÉMATOLOGIQUES
  申请人：JACKSON LAB

  公开号：WO2010124283A2

  公开（公告）日：2010-10-28

  Methods of treating a subject having, or at risk of having, a myeloproliferative disorder are provided according to embodiments of the present invention which include administering a therapeutically effective amount of an arachidonate 5- lipoxygenase (5-LO) inhibitor to the subject. Combinations of therapeutic agents are administered according to embodiments of the present invention. In some embodiments, two or more 5-LO inhibitors are administered to a subject to treat a myeloproliferative disorder. In further embodiments, at least one 5-LO inhibitor and at least one additional therapeutic agent are administered to a subject to treat a myeloproliferative disorder. Methods of inhibiting leukemia stem cells are provided according to embodiments of the present invention which include contacting leukemia stem cells with an effective amount of an arachidonate 5-lipoxygenase inhibitor.